- ## Our first, and biggest, clinic trial is registered
- #+BEGIN_VERSE
At STOP2030 we want to provide a pharmacological tool that helps at delivering WHO's elimination goals for soil-transmitted helminthiasis (STH). That is why we're happy to announce that we've completed the design of the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness). The details have been published in clinicaltrials.gov and the Pan African Clinical Trial Registry, and are now ready to be delivered to the Institutional Review Boards (IRBs) in Ghana and Kenya, where the trial will be conducted.
At STOP2030 we want to provide a pharmacological tool that helps at delivering WHO's elimination goals for soil-transmitted helminthiasis (STH). That is why we're happy to announce that we've completed the design of the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness). The details of the trial have been published in clinicaltrials.gov and the Pan African Clinical Trial Registry, and are now ready to be delivered to the Institutional Review Boards (IRBs) in Ghana and Kenya, where the trial will be conducted.
This clinical trial is a Cohort Event Study aimed at evaluating the safety and effectiveness of our fixed-dose coformulation (FDC) of albendazol and ivermectin within large populations, matched against the standard dose albendazole currently in use against STH. We expect to recruit around 20 thousand school-aged children between 5 and 17 years old in Kenya and Ghana.
Borja Robert
10 months ago